Literature DB >> 7950411

Distribution of immunoglobulins in squamous cell carcinoma of the head and neck.

C Neuchrist1, J Kornfehl, M Grasl, H Lassmann, D Kraft, K Ehrenberger, O Scheiner.   

Abstract

The immune response with respect to immunoglobulin production in the tumor was investigated in 23 patients with advanced squamous cell carcinomas of the head and neck. Immunohistochemical staining with monoclonal antibodies against IgG, IgM, IgA, IgD and IgE in the tumor was compared to normal hypopharyngeal mucosa. For IgG, IgA and IgM no significant differences between tumor and control tissues could be found. In contrast, a high number of IgE-positive cells was counted in most squamous cell carcinomas compared to normal mucosa. Most of these cells appeared as plasma cells. Regarding IgD the differences between tumor and control tissues, were less pronounced but also significant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7950411     DOI: 10.1159/000236714

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  14 in total

Review 1.  AllergoOncology: the role of IgE-mediated allergy in cancer.

Authors:  E Jensen-Jarolim; G Achatz; M C Turner; S Karagiannis; F Legrand; M Capron; M L Penichet; J A Rodríguez; A G Siccardi; L Vangelista; A B Riemer; H Gould
Journal:  Allergy       Date:  2008-07-26       Impact factor: 13.146

2.  Allergies and risk of head and neck cancer.

Authors:  Dominique S Michaud; Scott M Langevin; Melissa Eliot; Heather H Nelson; Michael D McClean; Brock C Christensen; Carmen J Marsit; Karl T Kelsey
Journal:  Cancer Causes Control       Date:  2012-06-19       Impact factor: 2.506

Review 3.  IgE immunotherapy against cancer.

Authors:  Lai Sum Leoh; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

4.  Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

Authors:  E Jensen-Jarolim; J Singer
Journal:  Clin Exp Allergy       Date:  2011-05-05       Impact factor: 5.018

5.  Evaluation of serum immunoglobulin (IgG, IgM, IgA) in potentially malignant disorders of oral cavity - A case control study.

Authors:  Vivek M Tarsariya; Dhaval N Mehta; Nilesh Raval; Hiren H Patadiya; Kanan Vachhrajani; Albert Ashem
Journal:  J Oral Biol Craniofac Res       Date:  2020-09-08

Review 6.  AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI).

Authors:  D Ferastraoaru; H J Bax; C Bergmann; M Capron; M Castells; D Dombrowicz; E Fiebiger; H J Gould; K Hartmann; U Jappe; G Jordakieva; D H Josephs; F Levi-Schaffer; V Mahler; A Poli; D Rosenstreich; F Roth-Walter; M Shamji; E H Steveling-Klein; M C Turner; E Untersmayr; S N Karagiannis; E Jensen-Jarolim
Journal:  Clin Transl Allergy       Date:  2020-07-17       Impact factor: 5.871

Review 7.  Mimotope vaccination--from allergy to cancer.

Authors:  Regina Knittelfelder; Angelika B Riemer; Erika Jensen-Jarolim
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

8.  Allergies and risk of head and neck cancer: an original study plus meta-analysis.

Authors:  Jenn-Ren Hsiao; Chun-Yen Ou; Hung-I Lo; Cheng-Chih Huang; Wei-Ting Lee; Jehn-Shyun Huang; Ken-Chung Chen; Tung-Yiu Wong; Sen-Tien Tsai; Chia-Jui Yen; Yuan-Hua Wu; Wei-Ting Hsueh; Ming-Wei Yang; Shang-Yin Wu; Jang-Yang Chang; Kwang-Yu Chang; Chen-Lin Lin; Fang-Ting Wang; Yi-Hui Wang; Ya-Ling Weng; Han-Chien Yang; Jeffrey S Chang
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

Review 9.  Mast Cells and Natural Killer Cells-A Potentially Critical Interaction.

Authors:  Liliana Portales-Cervantes; Bassel Dawod; Jean S Marshall
Journal:  Viruses       Date:  2019-06-04       Impact factor: 5.048

Review 10.  IgE immunotherapy: a novel concept with promise for the treatment of cancer.

Authors:  Debra H Josephs; James F Spicer; Panagiotis Karagiannis; Hannah J Gould; Sophia N Karagiannis
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.